Holen Sie sich die Stockscreener-App
0.782
1.23%
0.0095
Handel nachbörslich:
.78
-0.002
-0.26%
Schlusskurs vom Vortag:
$0.7725
Offen:
$0.77
24-Stunden-Volumen:
2.61M
Relative Volume:
0.58
Marktkapitalisierung:
$169.69M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-90.60M
KGV:
-1.2476
EPS:
-0.6268
Netto-Cashflow:
$-68.88M
1W Leistung:
-0.70%
1M Leistung:
+16.33%
6M Leistung:
-42.50%
1J Leistung:
+81.69%
1-Tages-Spanne:
$0.76
$0.8173
1-Wochen-Bereich:
$0.76
$0.8242
52-Wochen-Spanne:
$0.4253
$2.35
Tenaya Therapeutics Inc Stock (TNYA) Company Profile
Firmenname
Tenaya Therapeutics Inc
Sektor
Branche
Telefon
415-865-2066
Adresse
171 OYSTER POINT BLVD., SUITE 500, SOUTH SAN FRANCISCO
Compare TNYA vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TNYA
Tenaya Therapeutics Inc
|
0.782 | 167.63M | 0 | -90.60M | -68.88M | -0.6268 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Tenaya Therapeutics Inc Stock (TNYA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-06-10 | Eingeleitet | William Blair | Outperform |
| 2023-11-30 | Eingeleitet | Leerink Partners | Outperform |
| 2022-06-15 | Eingeleitet | H.C. Wainwright | Buy |
Tenaya Therapeutics Inc Aktie (TNYA) Neueste Nachrichten
What do we know so far from TN-201 trial? - Moomoo
TN-201 and TN-401 - Moomoo
TNYA Technical Analysis | Trend, Signals & Chart Patterns | TENAYA THERAPEUTICS INC (NASDAQ:TNYA) - ChartMill
Tenaya Therapeutics' gene therapy data highlights early heart rhythm improvements - MSN
Tenaya Therapeutics CMO Tingley Whittemore sells $2,476 in stock By Investing.com - Investing.com Australia
Tenaya Therapeutics CEO Ali Faraz sells $2,689 in shares - Investing.com UK
Tenaya Therapeutics CMO Tingley Whittemore sells $2,476 in stock - Investing.com UK
Tenaya Therapeutics CEO Ali Faraz sells $2,689 in shares By Investing.com - Investing.com South Africa
Tenaya Therapeutics SVP Tomohiro Higa reports $1,177 stock sale - Investing.com UK
Tenaya Therapeutics SVP Tomohiro Higa reports $1,177 stock sale By Investing.com - Investing.com Canada
Tenaya (TNYA) CEO sells 3,390 shares tied to RSU tax withholding - Stock Titan
Tenaya Therapeutics (TNYA) CMO sells 3,121 shares for tax withholding - Stock Titan
Tenaya Therapeutics (TNYA) SVP sells 1,485 shares to cover RSU taxes - Stock Titan
Canaccord Genuity Sticks to Their Buy Rating for Tenaya Therapeutics (TNYA) - The Globe and Mail
Tenaya Therapeutics, Inc. (TNYA) reports Q1 loss, misses revenue estimates - MSN
symbol__ Stock Quote Price and Forecast - CNN
H.C. Wainwright Maintains Tenaya Therapeutics(TNYA.US) With Buy Rating, Maintains Target Price $3 - Moomoo
CCORF Maintains Tenaya Therapeutics(TNYA.US) With Buy Rating, Maintains Target Price $5 - Moomoo
Tenaya Therapeutics, Inc. (TNYA) Discusses RIDGE-1 Phase Ib/II Data on TN-401 Gene Therapy for PKP2-Associated ARVCSlideshow (NASDAQ:TNYA) 2026-05-17 - Seeking Alpha
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Tenaya Therapeutics' Gene Therapy Data Highlights Early Heart Rhythm Improvements - Sahm
LifeSci Capital Maintains Tenaya Therapeutics(TNYA.US) With Buy Rating, Raises Target Price to $4 - Moomoo
Tenaya Therapeutics, Inc. (TNYA) Presents at Heart Failure 2026Slideshow (NASDAQ:TNYA) 2026-05-15 - Seeking Alpha
Chardan Capital Maintains Tenaya Therapeutics(TNYA.US) With Buy Rating, Maintains Target Price $8 - Moomoo
Tenaya Shares Rise on Positive Data From ARVC Study - Moomoo
Transcript : Tenaya Therapeutics, Inc.Special Call - marketscreener.com
Positive interim data from cohorts 1 and 2 of Tenaya's Ridge-1 phase 1b/2 clinical trial of TN-401 - marketscreener.com
Tenaya Therapeutics presents new RIDGE-1 trial results showing arrhythmia reduction in PKP2-associated ARVC - Traders Union
Positive Interim Data from Cohorts 1 and 2 of Tenaya’s RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 Demonstrated Consistent Reductions in Arrhythmia Burden for Adults with PKP2-associated ARVC - The Manila Times
Tenaya Therapeutics Reports Significant Reductions in Premature Ventricular Contractions in Interim Results from TN-401 Gene Therapy Clinical Trial - Quiver Quantitative
Tenaya reports interim gene therapy trial results for heart condition - Investing.com
Early TN-401 gene therapy trial eases dangerous heart rhythms - Stock Titan
Tenaya Therapeutics (TNYA) price target increased by 11.11% to 10.20 - MSN
TNYA.O Technical Analysis & Stock Price Forecast - Intellectia AI
Tenaya Therapeutics partners on parent attitudes survey for gene therapy in pediatric cardiomyopathy - Traders Union
Here's Why We're Watching Tenaya Therapeutics' (NASDAQ:TNYA) Cash Burn Situation - Moomoo
Eugene Braunwald legacy in HCM research honored by Tenaya Therapeutics - Traders Union
Tenaya Therapeutics (TNYA) Is Up 26.6% After TN-401 Data Buzz and Narrower Losses Has The Bull Case Changed? - Yahoo Finance
TradingKey - TradingKey
Why Tenaya Therapeutics (TNYA) Is Up 26.6% After New TN-401 Data Near-Term Catalysts - simplywall.st
LifeSci Capital Maintains Tenaya Therapeutics(TNYA.US) With Buy Rating, Maintains Target Price $3 - Moomoo
Finanzdaten der Tenaya Therapeutics Inc-Aktie (TNYA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Tenaya Therapeutics Inc-Aktie (TNYA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Tingley Whittemore | Chief Medical Officer |
May 18 '26 |
Sale |
0.79 |
3,121 |
2,477 |
215,497 |
| Higa Tomohiro | SVP, Finance |
May 18 '26 |
Sale |
0.79 |
1,485 |
1,178 |
118,267 |
| COLUMN GROUP III GP, LP | 10% Owner |
Feb 25 '26 |
Sale |
0.56 |
3,511,826 |
1,975,051 |
0 |
| COLUMN GROUP III GP, LP | 10% Owner |
Feb 24 '26 |
Sale |
0.62 |
658,440 |
405,138 |
1,649,281 |
0.98%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):